A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Trial to Evaluate the Efficacy and Safety of ONO-1110 in Patients With Social Anxiety Disorder
Latest Information Update: 13 Jul 2026
At a glance
- Drugs ONO 1110 (Primary)
- Indications Anxiety disorders
- Focus Therapeutic Use
- Sponsors Ono Pharmaceutical
Most Recent Events
- 08 Jul 2026 Status changed from active, no longer recruiting to completed.
- 20 Feb 2026 Status changed from recruiting to active, no longer recruiting.
- 19 Mar 2025 Status changed from not yet recruiting to recruiting.